Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Well Cell Global
Study ID
NCT07187479
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Physiologic Insulin Resensitization (PIR) — OTHER
    PIR is a physician-directed treatment that uses an exterior infusion pump to deliver insulin intravenously.

Study Details

The purpose of this research is to evaluate outcomes of physiologic insulin re-sensitization (PIR) in patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM).

Key Dates

Start date
Oct 14, 2025
Status verified
Oct 2025
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
120 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Physiologic Insulin Resensitization (PIR) Group
    Subject to receive Physiologic Insulin Resensitization (PIR)
  • No Intervention: Standard of Care (SOC) Group
    Subjects will receive standard of care

Primary Outcome Measure

Estimated Glomular Filtration Rate (eGFR) [ Time Frame: 12 and 24 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Arizona Kidney Disease and Hypertension CenterPhoenixArizona85027
Cynthia Carrizoza, MS, CCRP
[email protected]
602-997-0484
Sungchun Lee, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Phoenix, AZ

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Arizona Kidney Disease and Hypertension Center· Phoenix, AZ

Related Studies